PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancy
Blood · 14.12.2023 · 142 (24) · 2079-2091
DOI: 10.1182/blood.2023020331 ↗Kurz gefasst
Fachartikel in der Zeitschrift Blood, erschienen am 14.12.2023. Verfasst von Peter G Miller und 22 weiteren Autor:innen. Beteiligte Einrichtung: Center for Cancer Research, Massachusetts General Hospital, Boston, MA. Hauptthemen laut MEDLINE: Tumor Suppressor Protein p53, DNA Damage. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NHLBI NIH HHS, Howard Hughes Medical Institute.
Abstract (Originalsprache)
PPM1D encodes a phosphatase that is recurrently activated across cancer, most notably in therapy-related myeloid neoplasms. However, the function of PPM1D in hematopoiesis and its contribution to tumor cell growth remain incompletely understood. Using conditional mouse models, we uncover a central role for Ppm1d in hematopoiesis and validate its potential as a therapeutic target. We find that Ppm1d regulates the competitive fitness and self-renewal of hematopoietic stem cells (HSCs) with and without exogenous genotoxic stresses. We also show that although Ppm1d activation confers cellular resistance to cytotoxic therapy, it does so to a lesser degree than p53 loss, informing the clonal competition phenotypes often observed in human studies. Notably, loss of Ppm1d sensitizes leukemias to cytotoxic therapies in vitro and in vivo, even in the absence of a Ppm1d mutation. Vulnerability to PPM1D inhibition is observed across many cancer types and dependent on p53 activity. Importantly, organism-wide loss of Ppm1d in adult mice is well tolerated, supporting the tolerability of pharmacologically targeting PPM1D. Our data link PPM1D gain-of-function mutations to the clonal expansion of HSCs, inform human genetic observations, and support the therapeutic targeting of PPM1D in cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center for Cancer Research, Massachusetts General Hospital, Boston, MA.
- Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA.
- Harvard Medical School, Boston, MA.
- Broad Institute of MIT and Harvard, Cambridge, MA.
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
- Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Boston, MA.
ORCID-Profile: Peter G Miller, Adam S Sperling, Drew N Cohen, Chuqi Wang, Ni Yan, Steffen Boettcher, David T Scadden, R Coleman Lindsley, Benjamin L Ebert
Förderung
- NCI NIH HHS
- NHLBI NIH HHS
- Howard Hughes Medical Institute
Zitieren
APA
Miller, P. G., Sperling, A. S., Mayerhofer, C., McConkey, M. E., Ellegast, J. M., Da Silva, C., Cohen, D. N., Wang, C., Sharda, A., Yan, N., Saha, S., Schluter, C., Schechter, I., Słabicki, M., Sandoval, B., Kahn, J., Boettcher, S., Gibson, C. J., Scadden, D. T., …, & Ebert, B. L. (2023). PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancy. Blood, 142(24), 2079-2091. https://doi.org/10.1182/blood.2023020331
Vancouver
Miller PG, Sperling AS, Mayerhofer C, McConkey ME, Ellegast JM, Da Silva C, et al. PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancy. Blood. 2023;142(24):2079-2091. doi:10.1182/blood.2023020331
BibTeX
@article{Miller2023,
author = {Miller, Peter G and Sperling, Adam S and Mayerhofer, Christina and McConkey, Marie E and Ellegast, Jana M and Da Silva, Carmen and Cohen, Drew N and Wang, Chuqi and Sharda, Azeem and Yan, Ni and Saha, Subha and Schluter, Cameron and Schechter, Ilexa and Słabicki, Mikołaj and Sandoval, Brittany and Kahn, Josephine and Boettcher, Steffen and Gibson, Christopher J and Scadden, David T and Stegmaier, Kimberly and Bhatt, Shruti and Lindsley, R Coleman and Ebert, Benjamin L},
title = {PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancy},
journal = {Blood},
year = {2023},
volume = {142},
number = {24},
pages = {2079--2091},
doi = {10.1182/blood.2023020331}
}
EUVIMED